Avecho Biotechnology Limited

Equities

AVE

AU0000047441

Biotechnology & Medical Research

Market Closed - Australian S.E. 02:10:45 2024-04-19 am EDT 5-day change 1st Jan Change
0.004 AUD -20.00% Intraday chart for Avecho Biotechnology Limited 0.00% +14.29%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial MT
Avecho to Push Forward with Phase III Trial of Anti-Insomnia Drug MT
Avecho Biotechnology Secures Ethics Clearance for Phase Three Insomnia Trial MT
Avecho Biotechnology Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Avecho Biotechnology Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Avecho Biotechnology Achieves Two-Year Stability Milestone for CBD Capsule MT
US Patent Office Allows Avecho Biotechnology's Patent on 'Optimized' Manufacturing Method for Tocopheryl Phosphate Mixture MT
Avecho Biotechnology Signs Licensing Deal with Arthur Group for Development of Cancer Drugs MT
Avecho Biotechnology Begins Manufacturing for Oral Cannabidiol Capsules MT
Avecho Biotechnology Raises AU$2 Million Via Entitlement Offer; Shares Slip 20% MT
Avecho Biotechnology Conducts Entitlement Offer to Raise $11 Million to Fund Pivotal Phase Iii Clinical Trial CI
Avecho Biotechnology Limited Auditor Raises 'Going Concern' Doubt CI
Avecho Biotechnology Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Avecho Biotechnology Expands Research Partnership for Cannabidiol Medication MT
Avecho Biotechnology Limited Announces Ongoing Collaboration with Lambert Initiative CI
Athenex Pharmaceutical Division Submits Avecho's Vitamin K Injection to US FDA MT
Athenex Submits Avecho's Phytonadione to FDA Pre-IND CI
Avecho Biotechnology Secures Ethics Approval for Phase 3 Insomnia Trial MT
Avecho Biotechnology Limited Receives Ethics Approval for its Pivotal Phase III Clinical Trial Testing its Oral CBD Softgel Capsule for Insomnia CI
Avecho Biotechnology Signs Development Deal for TPM-enhanced Ibuprofen Gel for US market; Shares Up 10% MT
Avecho Biotechnology Limited Signs Development Agreement with Perrigo Company plc CI
Avecho Biotechnology Validates Bioavailability of Cannabinoid Product in Canine Study MT
Avecho Biotechnology Limited Announces Interim Results from Comparative Pharmacokinetic Studies Conducted in the Uk CI
Avecho Biotechnology Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Avecho Biotechnology Validates Efficacy of CBD Topical Gel Product in Hand Osteoarthritis Study; Shares Jump 8% MT
Chart Avecho Biotechnology Limited
More charts
Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. AVE Stock
  4. News Avecho Biotechnology Limited
  5. Avecho Biotechnology Secures Ethics Approval for Phase 3 Insomnia Trial